Genetic and specialty testing programs for inherited and acquired heart conditions
Cardiology conditions+Cardiology includes sponsored testing programs that offer no-cost or low-cost access to genetic and specialty testing for cardiomyopathy, arrhythmias, lipid disorders, and other hereditary or acquired cardiac conditions. These programs help identify underlying genetic risks, inform treatment and family screening decisions, and connect patients and clinicians with available sponsored testing options that support early diagnosis and proactive cardiac care.
10 programs found in Cardiology
The Alnylam Act® program supports eligible patients in the U.S. and Canada with no-cost access to genetic testing and counseling for acute hepatic porphyria (AHP), facilitating diagnostic clarity in this rare metabolic condition. Services are delivered by independent third-party providers and governed under a strict policy of de-identified data sharing for research purposes.
Sponsored by Biogen, this program offers no-cost genetic testing for Friedreich ataxia (FA) to support diagnosis and evaluation of patients with suspected or confirmed FA. Testing is available for individuals ≥16 years residing in the U.S. or Puerto Rico and must be ordered by a qualified provider.
The GACI Genetic Testing Program offers no-charge ultra-rapid whole genome sequencing through GeneDx for US infants under 12 months with imaging evidence of arterial calcification suspicious for Generalized Arterial Calcification of Infancy (GACI). Testing uses GeneDx's GenomeDx ultraRapid (uRGS) — key genes ENPP1 and ABCC6, whole-genome coverage — with results in as soon as 48 hours. The program is sponsored by BioMarin at no cost to the patient.
The HoFH Genetic Testing program offers no-cost genetic testing through Ambry Genetics for US patients with a history of severely elevated LDL-C, to help confirm a diagnosis of homozygous familial hypercholesterolemia (HoFH). Testing uses Ambry's FHNext, a 4-gene panel (APOB, LDLR, PCSK9, LDLRAP1) collected via saliva. The program is sponsored by Regeneron and includes no-cost genetic counseling.
The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers sponsored genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. The test is billed to insurance first; when a claim is denied or the patient is uninsured, the program's sponsor covers the cost of testing. Testing must be ordered by a qualified healthcare provider.
The Mission: Genome – Danon Disease Program offers no-charge Invitae testing for US-based patients with clinical suspicion of Danon disease. Testing includes LAMP2 as part of the Invitae Arrhythmia and Cardiomyopathy Panel. Eligible patients also receive no-charge post-test genetic counseling to support result interpretation and follow-up care.
The Mission: Genome – Danon Disease Program offers no-charge genetic testing through Ambry Genetics for US-based patients age 40 or younger with a clinical suspicion of Danon disease or an inherited cardiomyopathy. Testing uses Ambry's CardioNext®, a 92-gene cardiomyopathy and arrhythmia panel that includes LAMP2. The program is sponsored by Rocket Pharma and includes no-charge genetic counseling for eligible patients and families.
This sponsored program provides no-cost genetic testing for adult U.S. patients with a family history of hATTR, positive PYP or biopsy findings, or red-flag symptoms concerning for hATTR. Testing includes TTR gene analysis to support diagnostic evaluation, risk assessment, and clinical decision-making in patients with suspected hereditary transthyretin amyloidosis.
The CardioNavigATTR program is a no-charge genetic testing initiative for adult U.S. patients meeting specific criteria who are at risk for hATTR or cardiomyopathy. It offers a 36-gene cardiomyopathy panel (including TTR) to support diagnostic investigation, guide clinical decision-making, and identify hereditary risk in the cardiology setting.
Roadmap2Rare (Canada) provides complimentary genetic and biochemical testing for suspected rare diseases, delivered by Revvity Omics in collaboration with Sanofi Canada. The program is designed to address unmet testing needs and is available to Canadian clinicians. Test selection and treatment decisions remain at the discretion of the healthcare professional.
